Effects of Teriparatide in Postmenopausal Women With Osteoporosis
Phase 4
Completed
- Conditions
- Postmenopausal Osteoporosis
- Registration Number
- NCT00079924
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
- Postmenopausal women aged at least 50 years
- A previous clinical diagnosis of osteoporosis
- At high risk for fracture
- Current therapy for at least 18 months prior to study entry with either raloxifene HCl or alendronate Na
Exclusion Criteria
- History of metabolic bone disease other than osteoporosis
- History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in calcium values after beginning teriparatide
- Secondary Outcome Measures
Name Time Method Frequency of hypercalcemia, various calcium assessments, change in bone mineral density and tests of bone formation and resorption
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇺🇸Tulsa, Oklahoma, United States